Castle Biosciences (NASDAQ:CSTL) COO Sells $255,605.22 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 8,586 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $29.77, for a total value of $255,605.22. Following the completion of the sale, the chief operating officer directly owned 13,288 shares of the company’s stock, valued at approximately $395,583.76. This trade represents a 39.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL opened at $32.03 on Friday. The firm has a market capitalization of $978.52 million, a P/E ratio of -48.53 and a beta of 0.98. Castle Biosciences, Inc. has a one year low of $17.72 and a one year high of $44.28. The company’s fifty day moving average is $23.77 and its two-hundred day moving average is $26.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. The business had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. Analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Key Headlines Impacting Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and indicates potential upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest earnings exceeded expectations. Revenue was $99.86 million versus the $86.23 million consensus estimate, while the company reported a per-share loss of $0.07 compared with the expected $0.41 loss. Although CSTL remains unprofitable, the narrower-than-expected loss and stronger revenue support an improving operating outlook.
• Neutral Sentiment: Institutional investors own approximately 92.6% of CSTL’s shares. Recent purchases or stake increases by firms including AQR Capital Management, Amundi, Legal & General and Mirae Asset may provide shareholder support, but these ownership changes are not necessarily immediate trading catalysts.
• Negative Sentiment: Several company insiders disclosed sizable stock sales. Derek J. Maetzold sold more than 39,000 shares for approximately $1.21 million in August 4–5 transactions, while COO Kristen Oelschlager sold 8,586 shares worth about $256,000. Tobin W. Juvenal separately sold 1,301 shares for roughly $50,000. The sales reduced the insiders’ positions and could pressure sentiment, particularly following CSTL’s recent advance. However, all of the reported transactions were executed under pre-arranged Rule 10b5-1 trading plans, making them a less definitive bearish signal. Castle Biosciences insider sales

Institutional Investors Weigh In On Castle Biosciences

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in Castle Biosciences during the 2nd quarter valued at about $78,513,000. Deutsche Bank AG purchased a new stake in shares of Castle Biosciences in the second quarter valued at about $719,000. AIGH Capital Management LLC acquired a new stake in shares of Castle Biosciences in the second quarter valued at approximately $13,001,000. Global Retirement Partners LLC acquired a new stake in shares of Castle Biosciences in the second quarter valued at approximately $26,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Castle Biosciences during the 2nd quarter worth approximately $2,338,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on CSTL shares. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Robert W. Baird set a $36.00 price target on Castle Biosciences in a research note on Friday, July 31st. Canaccord Genuity Group lowered their price target on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Finally, BTIG Research raised their price objective on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.